At the 2012 meeting of the American Society for Clinical Oncology in Chicago this week, the Dana-Farber Cancer Institute's Levi Garraway chaired a session on research into different mechanisms of resistance to targeted anti-cancer therapeutics. In his research on melanoma, Garraway says he's seen that there are a number of mechanisms tumor can use to reactivate the pathways that sustain them. For example, in the MAP kinase pathway, RAF inhibitors, MEK inhibitors, and ERK inhibitors could all be used to block melanoma cell proliferation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.